Biogen's reprieve as critic recused from aducanumab panel, but analysts still read rejection in the tea leaves

Mayo Clinic neurologist David Knopman, M.D., has been kicked off an advisory committee assessing Biogen’s controversial Alzheimer’s disease hopeful aducanumab that's meeting later this week.

Knopman will now not help review the drug via the FDA advisory committee on Friday, with the regulator citing “conflicts of interest,” for his removal, according to Reuters.